Quest Diagnostics acquisition a strategic positive, says Maxim Maxim views Quest Diagnostics' acquisition of Solstas Lab Partners as a strategic positive and it recommends buying the stock following the news. The firm reiterates a Buy rating on the stock with a $73 price target.
Quest to acquire MemorialCare's laboratory outreach service business Quest Diagnostics and MemorialCare Health System announced they have entered into a definitive agreement for Quest to acquire MemorialCare Health System's laboratory outreach service business. The transaction is expected to be neutral to earnings in 2015. Quest and MemorialCare Health System expect to complete the acquisition in August. Financial terms were not disclosed.